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Autoimmunity occurs when the immune system incorrectly recognizes and attacks 
self-molecules. Current therapies involve broad immunosuppressants that are not 
curative and leave patients immunocompromised. Dendritic cells (DCs) are a target 
for new therapies because DCs influence the differentiation of immune effector 
cells. N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC), 
a glutamate receptor enhancer, modulates DC cytokine profiles to polarize T cells 
toward regulatory phenotypes (TREG ) that are protective in multiple sclerosis (MS). 
However, PHCCC treatment is limited by poor solubility, a short half-life, and 
toxicity. We hypothesized that controlled delivery of PHCCC from nanoparticles 
would alter DC function with reduced treatment frequency. PHCCC nanoparticles 
attenuated DC activation and promoted TREGs while reducing toxicity 30-fold. In 
  
mouse models of MS, these particles delayed disease and reduced severity compared 
to an equivalent dosing schedule of soluble drug. This outcome demonstrates 
controlled delivery of metabolic modulators can promote tolerance, suggesting a new 
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Chapter 1: Introduction and Background 
1.1 Organization of thesis 
This thesis describes a new idea for using nanoparticles to control the release 
of drugs that alter the metabolic function of immune cells to restrain autoimmune 
disease. The first chapter provides a survey of key background information in the 
areas of immune function, autoimmunity, and biomaterials. In the second chapter the 
significance of the thesis work to the field of immunotherapy is discussed. The third 
chapter describes the experimental methods of the research and the fourth chapter 
details the experimental results.  The fifth chapter contains a discussion of the results, 
and in the sixth chapter the conclusions of the research are summarized; potential 
areas for future investigation are also presented. 
1.2 Overview of adaptive immunity 
The key role of the immune system is to distinguish self-molecules and cells 
from pathogens and other non-self-molecules (1). In a healthy individual, foreign 
molecules or cells are recognized as non-self and attacked, while self-cells belonging 
to the host are ignored by immune system through a phenomenon termed “tolerance” 
(2). Central tolerance occurs in primary lymphatic organs such as the thymus and 
bone marrow, deleting immune cells which recognize self-antigens (3). Peripheral 
tolerance controls self-reactive immune cells that have escaped central tolerance and 
are present in the peripheral tissues not involved in the initial development and 
maturation of immune cells (4). When these processes fail, the immune system 




The immune response consists of two main arms, called innate and adaptive 
immunity. Innate immune responses recognize foreign pathogens largely through the 
sensing of danger signals (5). These danger signals generally consist of molecular 
patterns broadly conserved across pathogens and not present on host cells. Some 
examples include bacterial lipopolysaccharide (LPS) and viral RNA (5). Thus, the 
immune system has evolved to recognize and  react to pathogens through the sensing 
of these danger signals present on foreign pathogens. The innate immune response is 
not specific to individual pathogens, and responds to multiple pathogens containing 
danger signals. Although innate responses occurs quickly and provide a first line of 
defense, these mechanisms are not specific and do not exhibit immunological 
“memory”, responding identically to subsequent infections by the same pathogen. 
The adaptive immune response recognizes specific molecules, called antigens 
that are specific to individual pathogens. The first purpose of adaptive immunity is to 
initiate a primary response to infection, where lymphocytes called T and B cells 
recognize and attack pathogens expressing specific antigens (6). The subsequent 
purpose of adaptive immunity is to establish immunological memory towards 
previously encountered pathogens, allowing rapid and efficient recall responses to 
subsequent infection. This recall occurs through the generation of long lived memory 
cells after primary infection. Memory cells quickly respond and proliferate after 
recognition of a previously encountered pathogen, providing a pool of effector 
lymphocytes capable of combating the pathogen (7). This mechanism provides a 
much more rapid response to pathogens than the primary infection, allowing 




fundamental goal for vaccination is to generate immunologic memory toward specific 
pathogens and therefore protect the host from infection by these pathogens. 
The generation of an adaptive immune response is dependent on an important 
subset of the immune cells called antigen presenting cells (APCs); APCs can be seen 
as a bridge between innate and adaptive immunity (6). APCs create this link by 
processing and presenting antigens to T and B cells in lymph nodes and spleen – 
immune organs that orchestrate adaptive immunity. When APC presents an antigen to 
a naïve antigen-inexperienced lymphocyte with the correct co-stimulatory signals, 
lymphocytes become activated and expand (1). These lymphocytes are specific for 
the antigen presented by the APCs and then migrate from lymph nodes and spleen to 
seek out and perform effector functions such as secretion of inflammatory proteins 
and direct destruction of host-cells displaying antigen they are specific for (e.g., when 
infected by a virus) (9). 
Lymphocytes perform their effector functions through two types of immunity, 
termed humoral or cellular immunity (6). B cells are the main effector cells providing 
humoral immunity through the production of antibodies, which among other 
functions, neutralize extracellular pathogens such as bacteria, enhancing phagocytosis 
and destruction by macrophages and other innate immune cells (1) (Figure 1D). 
Cellular immunity is carried out by a class of T cells called CD8
+
 T cells, which 
recognize and lyse cells that have been infected with viruses or other intracellular 
pathogens (Figure 1D). Another class of T cells involved in cellular immunity, called 
CD4
+
 or helper T cells, support the adaptive and innate immune response through the 




Dendritic cells (DCs) are a class of professional APCs, which play a key role 
in generating adaptive immune response (11, 12). DCs patrol the periphery, where 
they specialize in phagocytosing particulate matter, including microbes, pathogens 
and apoptotic or necrotic cells (Figure 1A, 1B). DCs then migrate to lymph nodes 
and the spleen. At these sites, DCs process and present antigens contained in 
phagocytosed material to lymphocytes (13) (Figure 1C). As lymphocytes become 
activated and proliferate, they differentiate into different phenotypes that play distinct 
roles in adaptive immunity. The phenotype a lymphocyte differentiates to is largely 
controlled by signals presented and secreted by DCs during interaction with an 
antigen specific lymphocyte. DCs present costimulatory molecules (e.g., CD40, 
CD80) on their surface that ligate receptors expressed on lymphocytes to cause robust 
activation and proliferation. DCs also secrete a variety of cytokines, and the amount 
and relative levels of different cytokines drive the phenotypic polarization of 
lymphocytes. IL-12, for example, is important in promoting the differentiation of a 
subset of helper T cells, called TH1 cells, which drive a CD8
+ 
T cell mediated cellular 
immune response (14). In contrast, IL-4 drives helper T cells to differentiate to a 
phenotype called TH2, which is important in promoting B cell mediated humoral 




Figure 1. Schematic overview of the generation of adaptive immune response after 
exposure to an antigen. (A) Antigens present on pathogens are initially in the 
periphery. (B) DCs patrolling the periphery internalize pathogens and then migrate 
to lymph nodes. (C) DCs process and present antigens contained on pathogens to T 
and B cells in lymph nodes. (D) Activated T and B cells enter the periphery to 
perform cell mediated or humoral immunity upon encounter with the antigen they 
are specific for. 
 
 
1.3 Adaptive immunity in autoimmune disease     
Autoimmune disease occurs when the adaptive immune system aberrantly 
recognizes and attacks self-antigens. In terms of public health, some of the most 
widespread autoimmune diseases are type 1 diabetes, rheumatoid arthritis, lupus and 
multiple sclerosis (MS). During these diseases, immune cells seek out and attack self-




Figure 2. DCs orchestrate adaptive autoimmune responses through the polarization of 
CD4
+ 
T cells. (A) Graphical depiction of the differentiation of inflammatory T cells 
(TH1/TH17) or regulatory T cells (TREG) after interacting with a DC. Adapted from 
O’Shea and Paul, Science. 2010 (17) 
 
autoreactive lymphocytes and cells of the innate immune system, high levels of 
inflammatory cytokines, and production of autoreactive antibodies (15). 
Different phenotypes of lymphocytes play different roles in the pathology of 
autoimmune disease, with some phenotypes highly inflammatory, and others can 
actually control autoimmune disease through suppressive or regulatory mechanisms. 
Of particular importance in many autoimmune disorders are CD4
+
 T cells, where 
these cells differentiate into TH1, TH17 or TREG. TH1 and TH17 cells are highly 
pathogenic during autoimmunity, secreting inflammatory cytokines such as IFNγ and 
IL-17 (14). In contrast, TREGS are natural suppressor cells which help regulate 
immune function after infections are cleared – and as recent intense research efforts 
have shown – also play a critical role in supporting peripheral tolerance to control 







As discussed in Section 1.2, DCs play an important role in polarization of 
CD4
+
 T cells responses, and therefore are also often involved in autoimmune disease 
(Figure 2A). The magnitude and phenotype of the immune response, including 
malfunctions during autoimmunity, is largely driven by the integration of the levels of 
presentation of self or foreign antigen, and the types and expression levels of 
activation markers and cytokines produced by DCs and lymphocytes(17). Expression 
of high levels of activation markers and secretion of inflammatory cytokines by a DC 
during the interaction with a T cell will drive the polarization of inflammatory 
phenotypes, while absence of activation markers and presence of regulatory cytokines 
will polarize T cells toward regulatory phenotypes. IL-6, for example, can promote 
the differentiation of TH17 cells, while inhibiting the differentiation of TREG (18). 
Additionally, as DCs polarize T cells, these cells secrete cytokines (e.g., IFNγ during 
inflammation; TGFβ during regulation) that exert autocrine effects as well as 
paracrine effects on other nearby T cells, further amplifying this polarization (14).  
1.4 The pathology of multiple sclerosis and current treatments 
MS is an autoimmune disorder which occurs when the adaptive immune 
system attacks myelin, a protein which insulates axons of neurons. MS affects over 
2.1 million people and is the most common autoimmune disorder (19). 
Autoinflammation in MS results in chronic demyelination in the central nervous 
system (CNS). This demyelination causes disruption in neuronal signaling resulting 
in severe symptoms such as loss of vision, paralysis, and death (20). The pathology of 
MS is largely driven by autoreactive TH1 and TH17 cells that infiltrate the CNS and 




myelin can be suppressed by TREGS and other regulatory mechanisms (16, 21, 22). 
Therefore a common therapeutic strategy for MS is to polarize T cells toward 
regulatory (TREG) and away from inflammatory phenotypes (TH1/TH17). 
Treatments for M.S have historically aimed to inhibit the self-reactive 
immune response and the resulting autoinflammation. Broad immunosuppressants 
administered systemically, such as steroids or immunosuppressive cytokines, have 
traditionally been used as treatments (23). More recently monoclonal antibodies have 
been approved for treatment, which are able to target more specific pathways (24). 
However, these treatments are not curative, require life-long administration, and still 
leave patients immunocompromised. A new strategy being investigated is the 
promotion of myelin-specific tolerance, which would offer the potential to inhibit 
autoimmune reactions toward myelin while leaving the rest of the immune system 
functional and able to protect against foreign pathogens (25). As in vaccination and 
other immunotherapies, these strategies can be further enhanced through better 
control over the delivery of the immune signals involved in polarizing T cells toward 
tolerance, ideas discussed below in Sections 1.4 and 1.5. 
1.5 Use of biomaterials for modulating immune function  
Biomaterials offer many favorable properties which can be harnessed to 
enhance vaccination and immunomodulation (26, 27). Many biomaterials, such as 
biodegradable polymers (28-30), liposomes (31), and self-assembling complexes (32) 
can be used to encapsulate and control the delivery of immune signals, including 
antigens, adjuvants – substances that increase the potency of vaccines – and 




cargos can be encapsulated, providing protection from degradation, controlled and 
sustained co-delivery, and targeting to specific immune cells or tissues (29, 38-40). 
APCs specialize in phagocytosing particulate material and readily endocytose 
microparticles (MPs) or nanoparticles (NPs). Thus these materials allow co-delivery 
of encapsulated immune signals into the cytosol. This is an important feature for 
vaccines and immunotherapies because it can enhance the processing and 
presentation of antigens, ensure that adjuvants and immunomodulators  –  signals that 
modify the function of the immune response – reach APCs together, as well as 





T cells). Additionally this mechanism provides localization of immunomodulators 
and adjuvants to APCs, allowing potential dose sparing while reducing systemic 
exposure and potential toxicities (41). 
The level of activation and balance between inflammatory and regulatory 
cytokines secreted by a DC when it presents an antigen is key in driving the balance 
between immunity and tolerance toward that specific antigen. This balance between 
immunity and tolerance is at the core of strategies for vaccination and more specific 
therapies for autoimmunity, respectively. A common vaccination strategy to safely 
generate an effective adaptive immune response against a desired pathogen is to use 
subunit vaccines, formulations consisting only of well-defined antigens isolated from 
a specific pathogen. These antigens are generally poorly immunogenic, and without 
stimulatory molecules do not generate robust immune responses. Toll-like receptors 
(TLRs) are receptors present on cells of the innate immune system which function to 




(TLRas) serve as adjuvants by potently activating DCs in a well-defined manner. 
These molecules have also been used in combination with antigens to synergistically 
enhance vaccination (43). However, systemic administration of adjuvants and 
antigens does not ensure that both components reach DCs together, so DCs may not 
be activated in the presence of the antigen. In the context of autoimmunity, a 
therapeutic treatment may conversely involve administering regulatory signals to DCs 
with the autoantigen, in order to decrease DC activation during the presentation of 
autoantigens; these effects are known to encourage the promotion of TREGs are 
specific to the self-antigen (44). To this end, a new materials-based strategy to target 
multiple immune signals to DCs is to encapsulate and co-deliver the signals in NPs or 
MPs (34, 45).  
The kinetics and concentrations of immune signals during vaccination are key 
parameters affecting the properties of the resulting immune response (46). 
Biomaterials offer control over the dosing and persistence of immune signals, and can 
be harnessed to enhance vaccination and immunotherapies. For example, NPs provide 
sustained concentrations of cargo as it is released over time. This property can be 
tuned to better recapitulate kinetics of antigens and danger signals which would occur 
in response to infection, and therefore generate a more substantial immune response 
(27).  
In addition to delivery of vaccines, biomaterial-mediated controlled delivery 
of small molecule immunomodulators can enhance immunotherapies (30, 34). 
Hydrophobic small molecules are a large and important class of immunomodulatory 




Additionally, hydrophobic small molecule drugs typically have short half lives in 
vivo, and are rapidly cleared from the body after systemic administration. Controlled 
delivery of immunomodulators can address these limitations, alleviating the need for 
frequent high dose administrations, which potentially cause toxicities and off target 
effects (47, 48). 
Lymph nodes are key centers for the generation of immune responses (49), 
and are therefore the site immune signals much reach to modulate the adaptive 
immune response. Biomaterials offer the ability to target lymph nodes through 
passive lymphatic drainage (50) or actively target immune signals to lymph nodes. 
NPs in the range of 20-50nm passively drain through lymphatics to the lymph nodes 
where they are retained and taken up preferentially by LN-resident DCs and 
macrophages (45, 51). Larger NPs as well as MPs are phagocytosed by APCs at the 
site of the injection, and are then trafficked to lymph nodes by these cells (52). In 
addition to passive targeting, active targeting of NPs to LNs or LN-resident APCs can 
be achieved through the conjugation of a variety of targeting ligands or receptors (29, 
38, 39).  These provide strategies to deliver a variety of immune signals, such as 
antigens, adjuvants and drugs to lymph nodes more effectively to bias how 
lymphocytes differentiate. 
1.6 Application of biomaterials to promote tolerance 
Recent insights into the pathology and mechanisms of autoimmune reactions 
have led to exploration of many potential strategies for autoimmune therapies. A clear 
consensus exists that some autoreactive immune cells evade central tolerance and 




are kept in check by peripheral tolerance. In the case of autoimmune diseases, these 
autoreactive cells overcome peripheral tolerance and drive autoimmune reactions. 
Strategies for autoimmune therapies generally aim to suppress inflammation, or more 
recently, to restore peripheral tolerance by 1) eliminating self-reactive immune cells, 
or 2) generating TREGS that can suppress the function of these cells. Biomaterials can 
be harnessed to this end through the controlled delivery of regulatory signals (53). 
Regulatory signals, including small molecule drugs or biologics, may be delivered 
alone to broadly suppress autoreactive responses with reduced toxicity, or may be co-
delivered with self-antigens in an effort to promote TREGS that can specifically 
inactivate lymphocytes specific for the self-antigens. An additional strategy includes 
using biomaterials as platforms to change the way self-antigens are processed to 
promote differentiation of TREGS over inflammatory cells (44).  
Biomaterial mediated controlled delivery of a variety of regulatory signals, 
including small molecule drugs, enzymes, and cytokines has been investigated to 
restore tolerance. Poly(lactic-co-glycolic acid) (PLGA) NPs encapsulating 
mycophenolic acid (MPA), which is a potent immunosuppressant, have been used to 
tolerize the immune system toward allografts in transplantation (30). Soluble 
treatment of MPA is effective in prolonging allograft survival, but requires frequent 
high dose injections which often result in toxic side effects. Systemic administration 
of PLGA NPs encapsulating MPA resulted in accumulation of NPs in spleens and 
LNs, and NPs were preferentially taken up by APCs. This resulted in upregulation of 




responses directed against antigens present on the allograft and improved allograft 
survival.  
Biomaterials themselves can also act as a regulatory signal through 
modulating how APCs interact with and process self-antigens. The pathways through 
which APCs internalize soluble and particulate material are largely a function of size 
and can be mediated by a variety of receptors (54). Internalization of apoptotic cells 
plays an important role in the maintenance of tolerance to self-antigen. As a strategy 
to mimic this tolerogenic pathway, polystyrene or PLGA MPs conjugated to myelin 
peptides have been used to restrain autoimmune reactions in mouse models of MS 
(55). These therapeutic effects are dependent on the uptake of the MPs in the spleen 
through the MARCO scavenger receptor, which specializes in uptake and clearance 
of cellular debris (56). 
NPs have also been used to co-deliver regulatory signals and self-antigens as a 
strategy to restore tolerance to specific antigens while leaving the rest of the immune 
system unaltered (28, 34, 57). Co-delivery of rapamycin and myelin autoantigen with 
PLGA NPs effectively inhibits autoimmune reactions directed towards myelin in 
mouse models of MS (34).  Rapamycin is a tolerogenic small molecule that inhibits 
the mTOR pathway, a pathway involved in a variety of cellular division and 
maintenance processes. Inhibition of this pathway in DCs can modulate their T cell 
phenotype to promote differentiation of TREGS. NP mediated co-delivery of myelin 
antigen and rapamycin to DCs caused the generation of TREGS in an antigen specific 
manner, which suppresses the immune response toward myelin antigen, resulting in 




recent strategies demonstrating that DCs can be effectively modulated to control the 
immune response for therapeutic effects in autoimmune disease have motivated the 
investigation of targeting other DC pathways such as metabolic function. However, 






Chapter 2: Project Significance
ǂ
  
2.1 Glutamate signaling to modulate DCs for autoimmune therapy 
High levels of glutamate are present in the CNS during autoinflammation in 
MS patients, leading to a state of excitotoxicity that exacerbates inflammation and 
depletes oligodendrocytes – the cells responsible for remyelinating neurons (58, 59). 
The metabotropic glutamate receptor (mGluR) family helps control these effects, 
resulting in inflammation or protection against excitotoxicity, depending on the 
relative presence and activity of each mGluR receptor in the CNS during disease (58-
61). In particular, metabolism of glutamate through mGluR4 reduces N-Methyl-D-
aspartate toxicity in cortical neurons and kainate mediated toxicity in 
oligodendroctyes. (61, 62).  
In addition to serving as a neurotransmitter, glutamate also functions as an 
immunomodulator by interacting with glutamate receptors expressed on the surface of 
DCs or other immune cells (63). As discussed in Section 1.3, DCs play a key role in 
initiating adaptive immunity by processing and presenting exogenous antigens, or in 
the case of autoimmune diseases such as MS, self-antigens (e.g., myelin). 
Presentation of these antigens to a cognate T cell drives antigen-specific proliferation 
and differentiation. The magnitude and type of T cell response is dictated in part by 
the activation and inflammatory state of DCs during the formation of an immune 
synapse with a T cell (12). For example, suppression of DC activation can induce 
secretion of regulatory cytokines that diminish T cell expansion and shift the 




During inflammation, DCs release glutamate that regulates T cell activation 
and proliferation by binding glutamate receptors on DCs and T cells (63, 67, 68). The 
identity and abundance of the mGluRs that are bound by glutamate alters cyclic 
adenosine monophosphate (cAMP) levels, modulating the balance of inflammatory 
and regulatory cytokines that direct the resulting immune response. This mechanism 
has stimulated interest in controlling glutamate receptor signaling as one route to 
regulate immune cell function in new therapies for MS (68-70). The Di Marco group 
recently demonstrated that mGluR4 is expressed at high levels on DCs and exerts an 
immunoregulatory function by showing that DCs with defective mGluR4 signaling 
preferentially polarize T cells to inflammatory TH17 phenotypes. This work further 
revealed that N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide 
(PHCCC), a small molecule positive allosteric modulator of mGluR4, can bias T cell 
function toward tolerance during autoimmunity in mice (62, 68). Prophylactic 
treatment of mice with PHCCC during Experimental Autoimmune Encephalomyelitis 
(EAE) – a mouse model of MS – inhibited clinical symptoms of neuroinflammation 
by inducing regulatory cytokine profiles in DCs that promoted TREGS and reduced 
TH17 cells (10). However, the use of PHCCC is hindered by poor solubility and a 
short half-life (71), with neurological symptoms and paralysis returning within one 
day after daily systemic injections were stopped (68). 
2.2 Hypothesis and Research Strategy 
To address the challenges associated with PHCCC treatment, we hypothesized 
that controlled release of PHCCC might maintain or improve efficacy while offering 




sustained release of small molecules that control immune cell metabolism can 
promote tolerance and restrain autoimmunity. In these studies we employed a well-
understood PLGA NP platform to test if controlled release of these drugs would alter 
DC function, promote regulatory T cells, and more effectively control disease in 







3.1 PHCCC NPs 
3.1.1 Synthesis 
PLGA NPs encapsulating PHCCC were synthesized by nanoprecipitation. The 
solvent phase was prepared by dissolving 25mg of PLGA in 1.5mL acetone. For 
samples loaded with PHCCC, this polymer solution was transferred to a vial 
containing the appropriate mass of dried PHCCC. For samples loaded instead with 
DiO, 5µL of 1µM DiO solution was added to the polymer solution. The non-solvent 
phase consisted of 20mL deionized water with 0-2% polyvinyl alcohol (PVA). The 
solvent phase was then uniformly injected through a 31g needle under the surface of 
the non-solvent phase while mixing with a magnetic stir bar. The solvent was 
evaporated for 3 hours, leaving a suspension of stabilized NPs. The suspension was 
poured through a 40µm cell strainer then centrifuged for 75 min at 4 C at 3000g. The 
supernatant was decanted and the NPs were resuspended in deionized water. 
3.1.2 Particle Characterization 
To measure PHCCC encapsulation, NPs were dried and dissolved in DMSO. 
The absorbance was then measured at 300nm on a UV-VIS spectrophotometer and 
corrected by subtracting the absorbance value measured for empty NPs dissolved at 
the same mass concentration in Dimethyl-sulfoxide (DMSO). Absorbance values 




Particle size distributions were measured by laser diffraction using a Horiba Partica 
LA 950V2. 
To measure release kinetics, known concentrations of PHCCC NPs were 
incubated at 37 C in RPMI 1640 media under sink conditions to eliminate release 
effects arising from saturated drug solution. At each interval PHCCC NPs were 
centrifuged at 18,000g for 5 minutes, and PHCCC concentration in the supernatants 
was determined by UV-VIS spectrophotometry as above. Particles were then 
resuspended in media and returned to incubation at 37 C. The cumulative PHCCC 
released was calculated at each time and normalized to the total loading to calculate 
the percent of PHCCC released. 
 
3.2 In vitro effects of PHCCC NP properties on DCs 
3.2.1 Uptake 
 Isolated DCs were plated in flat bottom 96 well plates and incubated in media 
with the specified concentrations of DiO NPs for 90 minutes. Cells were washed with 
PBS to remove free NPs, and then detached using cold, 10mM 
ethylenediaminetetraacetic acid  (EDTA). Detached cells were washed with cold PBS 
+ 1% BSA, then resuspended in 4',6-diamidino-2-phenylindole (DAPI) (5µg/mL) in 
PBS + 1% BSA. DCs were analyzed by flow cytometry to determine the percentages 
of cells positive for DiO (particles). For analysis of particle uptake by microscopy, 
splenic CD11c
+
 DCs were plated in 35mm dishes and incubated in media with DiO 
NPs for 90 minutes. Cells were washed with PBS to remove free NPs, then fixed with 




temperature in the dark for 10 minutes with 5µg/mL wheat germ agglutinin Texas 
Red conjugate in PBS. The cells were then washed with PBS, labeled with Hoechst 
nuclear stain diluted to 2µg/mL in PBS. Cells were imaged using a Leica SP5 X laser 
scanning confocal microscope with a 63X objective. 
3.2.2 Reduction in toxicity 
 To analyze toxicity of soluble PHCCC or PHCCC delivered in NP format, 
CD11c
+
 cells isolated from splenocytes (1x10
5
 cells/well) were stimulated with LPS 
(1µg/mL) and treated with equivalent concentrations of PHCCC delivered in soluble 
or NP format. After 18 hours toxicity was analyzed by flow cytometry by staining 
with DAPI and quantifying the percentage of DAPI
-
 events. Relative viability was 
calculated by normalizing the percent of viable cells to the value of the untreated LPS 
stimulated control. The fold-decrease in toxicity was calculated by dividing the 
relative viability of cells treated with PHCCC NPs by the value for cells treated with 
soluble PHCCC at 400µM. 
 
3.3 In vitro DC immunodulation with PHCCC NPs 
3.3.1. Effect of PHCCC NPs on DC activation and cytokine secretion 
 For analysis of DC surface activation markers and cytokine secretion levels, 
CD11c
+
 cells isolated from splenocytes (1x10
5
 cells/well) were stimulated with LPS 
(1µg/mL) and left untreated or treated with soluble PHCCC (40µM), PHCCC NPs, or 
empty NPs using equivalent particle doses/masses. For soluble PHCCC controls, 




40µM in media. After 18, 44 and 68 hours, cells and cell culture supernatants were 
collected. IL-6 and IL-10 concentrations in the supernatants were determined by 
ELISAs (BD Biosciences). The collected cell pellets were stained as above for 
viability (DAPI
-
), CD11c (APC-Cy7) and activation/costimulatory markers (i.e., 





 negative events. 
3.3.2 Effect of PHCCC NPs on DC antigen presentation 
For analysis of DC antigen presentation, DCs stimulated with LPS were 
treated with PHCCC, PHCCC NPs, and empty NPs as in DC activation studies. After 
18 hours, cells were incubated for 2 hours with SIINFEKL peptide (5µg/mL), or with 
MOG35-55 (5µg/mL) as an irrelevant peptide control. Cells were then stained for 
presentation of SIINFEKL via the H-2kb complex using an antibody which binds 






3.4 In vitro effect on PHCCC NPs on T cell polarization 
3.4.1 Effect of PHCCC NPs on T cell phenotype  
Isolated DCs (1x10
5
 cells/well) were stimulated with LPS (1µg/mL) and 
MOG (10µg/mL) and treated with soluble PHCCC (40µM), PHCCC NPs, or empty 
NPs. After 18 hours, splenic CD4
+
 T cells isolated from 2D2 mice (3x10
5
 cells/well) 
were added to the DC culture. After an additional 2 days, supernatants were collected 
and IFN concentrations were measured by ELISA (BD Bioscience). Cells from these 
















3.4.2 Effect of PHCCC NPs on T cell proliferation  
For proliferation studies, splenic CD4
+
 T cells isolated from 2D2 mice were 
incubated with carboxyfluorescein succinimidyl ester (CSFE) before addition to DCs 
treated with LPS, peptide, and particles identically as described in Section 3.4.1. The 
T cells were labeled by resuspension in media at 50x10
6
 cells/mL then incubation in 
CSFE at a final concentration of 5µM for 5 minutes at room temperature. Cells were 
washed four times with media, then added to the DC cultures. Cells were collected 72 
hours later and analyzed by flow cytometry to determine the extent of T cell 




 cells). Analysis was performed 
using FlowJo software (Treestar). 
 
3.5 In vivo effect of PHCCC NPs on restraining autoimmune reactions 
3.5.1 Efficacy of PHCCC NPs with different treatment regimens 
All animal research and care was carried out in accordance with local, state, 
and federal regulations and under guidelines approved by the University of Maryland 
IACUC. EAE was induced in 10 week old C57BL/6 mice as previously described(72, 
73). Briefly, mice were immunized with two subcutaneous (s.c.) injections of 
emulsions prepared from complete Freund’s adjuvant (CFA) and 100μg of MOG35-55 




pertussis toxin in 100µL of PBS was injected intra-peritoneal (i.p.) on the day of 
immunization and again the following day.  
Soluble PHCCC , PHCCC NPs (each group n=6, dosed with 3 mg/kg with 
respect to drug dose) were administered s.c. at the tailbase every 3 days or every 5 
days beginning on the day of EAE induction (day 0). For soluble treatment, PHCCC 
was dissolved in sesame oil (68) and PHCCC NPs were suspended in deionized 
water. Empty NPs at the same mass as the PHCCC NP treatments were included as 
controls. Mice were weighed and scored daily for signs of disease using an accepted 
clinical pathology scoring scale: 0, no symptoms; 1, limpness in entire tail; 2 
weakness in hind legs; 3, paralysis of hind legs or paralysis of one front leg and one 
hind leg; 4, moribund. Mice were euthanized according to defined endpoints if a 
score of 4.5 was reached, upon a score of 4.0 for 2 days, or upon 25% weight loss 
(with respect to initial weight). 
 
3.6 Statistical analysis 
 
 Statistical analysis was undergone for in vitro and in vivo studies conducted 
utilizing the optimized NP formulation. Student’s T test was used when comparing 
two groups, and one way ANOVA with a Tukey post-hoc analysis was used with 
comparisons of three of more groups. For EAE studies, unpaired T tests were used to 
compare mean clinical scores between groups at each study day. P values to 
determine statistical significance are indicated as*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 







4.1 Synthesis and physiochemical characterization of PHCCC NPs 
 
PLGA NPs synthesized by nanoprecipitation are a well characterized platform 
that has been used extensively for the controlled delivery of small molecule drugs. 
We therefore used this platform to test the new idea that controlled release of the 
glutamate receptor enhancer, PHCCC, might modulate immune cell function to 
restrain autoimmune reactions with reduced toxicity and frequency of treatment.  
PHCCC was successfully encapsulated in NPs at high levels, with PHCCC 
loading levels correlated with increasing ratios of drug to polymer input. Loading was 
optimal at a drug:polymer input ratio of 0.2, which resulted in a drug loading level of 
73.2 ± 25.9µg of PHCCC per mg of NPs (Table 1). Further increasing the drug to 
polymer ratio to 0.4 or higher did not result in any further increase in loading. NPs 
exhibited relatively uniform size distributions, with mean diameters ranging from 
114-185nm depending on the drug to polymer ratio (Figure 3A, 3B). 
 






To examine the release kinetics of PHCCC from NPs, particles were 
incubated in media at 37C. PHCCC NPs released 66.3% of drug over the first 4 hrs, 
followed by a slower release rate that accounted for release of 86.3% of total 
encapsulated drug after 48 hours (Figure 3C). 
 
4.2 Effects of NP mediated controlled delivery of PHCCC on DCs 
After determining PHCCC NPs could be synthesized in the nm range and 
released drug over time, we investigated how these general properties would affect 
the uptake and viability of primary DCs. To test the ability of DCs to internalize NPs, 
fluorescently-labeled empty NPs were incubated with CD11c
+
 splenic DCs for 90 
minutes. Flow cytometry analysis of these samples revealed a dose dependent uptake 
of NPs with up to 58.4 ± 2.8% of live, CD11c
+
 cells positive for NPs (Figure 3D). 
Visualization of cells by confocal microscopy confirmed these results, showing 





Figure 3. NPs synthesized by nanoprecipitation are internalized by DCs and eliminate 
toxicity observed from soluble PHCCC. (A) SEM image of PHCCC NPs. (B) 
Histogram showing size distribution of PHCCC NPs synthesized with 2% PVA and a 
drug to polymer ratio of 0.2. (C) In vitro release kinetics of PHCCC NPs. (D) Primary 
splenic DCs were incubated for 90 min with fluorescent NPs, and the percent of DCs 
positive for NP uptake was quantified by flow cytometry. (E) Confocal microscopy 
image of DCs treated as in (D), demonstrating colocalization of NPs (green) within 
cells. DCs were stained with a Texas Red wheat germ agglutinin conjugate (red) and 
Hoechst nuclear stain (blue). (F) Primary splenic DCs were stimulated with LPS 
(1µg/mL) and treated with PHCCC in soluble or NP form. Viability relative to LPS 
stimulated cells was quantified by DAPI staining and analysis by flow cytometry. All 
data were collected in triplicate and are representative of 3 similar experiments. 
 
To assess the toxicity of PHCCC on immune cells, we stimulated DCs with 
LPS, along with varying doses of PHCCC in soluble form or loaded in NPs. After 18 
hours, only 2.2% of cells treated with LPS and soluble PHCCC remained viable 
relative to cells treated with LPS alone (Figure 3F). Strikingly, 83.6% of DCs 
remained viable following treatment with LPS and an equivalent concentration of 




4.3 Immunomodulation of DCS by PHCCC NPs in vitro 
 
After determining that NPs were readily internalized by DCs with minimal 
toxicity, we investigated the immunomodulatory properties of PHCCC encapsulated 
in NPs. Optimization studies of the NP formulation were conducted. The effect of 
NPs synthesized with varying concentrations of PVA stabilizer and different 
drug:polymer ratios on DC inflammatory cytokine secretion was investigated. This 
was performed in order to determine an optimal NP formulation which would 
maximize the effects of encapsulated PHCCC with minimal effects from the empty 
NP carrier. An optimized formulation was chosen, and the effects of a range of doses 
of PHCCC NPs synthesized with this formulation were tested inflammatory cytokine 
secretion, activation marker expression and antigen presentation by DCs. 
To determine what range of drug input levels in NPs would alter DC function, 
DCs were stimulated with LPS and incubated with a fixed dose of PHCCC loaded in 
NPs that were prepared using different drug:polymer ratios (Figure 4, green bars). 
Empty NP (Figure 4, gray bars) controls were prepared at the same mass of NPs (i.e., 
polymer) used for PHCCC NPs to confirm that the effect of PHCCC NPs was 
attributable to encapsulated PHCCC. The levels of IL-6 and IL-10 secretion were 
then measured in the supernatants to determine if PHCCC NPs reduced the 
inflammatory effects caused by LPS treatment. IL-6 levels generally increased over 
the 3 day incubation, but at each time point, DCs treated with LPS and a fixed drug 
dose loaded in PHCCC NPs, caused a significant reduction in IL-6 secretion 
compared with cells treated with LPS only (Figure 4A-C). These reductions were not 




Figure 4. Impact of PHCCC loading in NPs on DC cytokine secretion. CD11c
+
 cells 
isolated from spleens were stimulated with LPS (1µg/mL) and treated with soluble 
PHCCC (40M) or PHCCC NPs (100 M with respect to drug) synthesized by fixing 
polymer mass and varying drug input (drug:polymer ratio). Cells treated with equivalent 
masses of empty NPs were also included as controls. Supernatants were collected and 
the concentrations of IL-6 (A-C) and IL-10 (D-F) were measured by ELISA at 18 hours 
(A,D), 44 hours (B,E), and 68 hours (C,F). Samples were prepared in triplicate and data 
are representative of results from at least 3 similar experiments.  
particles generally did not cause a significant change in IL-6 level. However, at 
empty particle masses equivalent to those used for the lowest drug:polymer ratio (i.e., 
highest polymer mass), empty NP controls had a modest effect on IL-6 secretion. 
PHCCC also decreased IL-10 secretion, but the kinetics of this reduction after 
treatment with soluble PHCCC or PHCCC NPs was delayed compared with the 
timeline observed for IL-6 (Figure 4D-F). The effects of PHCCC NPs were evident 
at 44 hours and 68 hours, but not at the earlier time point of 18 hours where no 
differences were observed between empty NPs and PHCCC NPs (Figure 4D-F).  
A further optimization study was performed by varying the stabilizer (i.e., 




Figure 5. Impact of PVA concentration in PHCCC NPs on DC cytokine secretion. 
CD11c
+
 splenocytes were stimulated with LPS (1µg/mL) and treated with soluble 
PHCCC (40M), PHCCC NPs (100µM) synthesized with different PVA 
concentrations, or equivalent masses of empty NPs. Supernatants were collected and 
IL-6 (A-C) and IL-10 (D-F) concentrations were measured by ELISA at 18 hours 
(A,D), 44 hours (B,E), and 68 hours (C,F). 
ratio was selected since PHCCC loading was most efficient using this drug input 
ratio, and minimal background effects were observed from empty particles. In the 
stabilizer studies, the effect of empty NPs on cytokine secretion was minimized at a 
PVA concentration of 2% (Figure 5). Therefore particles synthesized using these two 
parameters were chosen for all subsequent studies. 
 
 
Using the optimized particle formulation, we next identified a dosing range 
where PHCCC NPs modulate DC function by stimulating DCs with LPS and treating 
with a range of PHCCC NP doses. For IL-6, a dose dependent response was observed 




Figure 6. PHCCC NPs alter cytokine secretion by DCs in a dose-dependent manner. 
CD11c
+
 cells isolated from spleens stimulated with LPS (1µg/mL) were treated with 
soluble PHCCC (40M), PHCCC NPs at decreasing doses, or equivalent masses of 
empty NPs. Supernatants were collected and the concentrations of IL-6 (A-C) and IL-
10 (D-F) were measured by ELISA at 18 hours (A,D), 44 hours (B,E), and 68 hours 
(C,F). Samples were prepared in triplicate and data are representative of results from 
at least 3 similar experiments.  
 
reduction in IL-6 secretion (Figure 6A-6C). A similar trend was observed at 44 hours 
and 68 hours for IL-10, but was less clear at the 18 hour time point (Figure 6D-4F). 
Empty NP controls did not significantly suppress IL-6, but caused a modest decrease 
in IL-10 levels at 44 hours and 68 hours compared with LPS. However, at all three 
time points PHCCC NPs significantly decreased cytokine secretion compared to 
empty NPs.  
T cell proliferation and phenotype (e.g., TH17 vs. TREG) are dependent on the 
levels and balance of antigen and co-stimulatory signals presented by DCs. To test the 
hypothesis that PHCCC NPs would decrease stimulatory cues presented by DCs, DCs 
were stimulated with LPS and left untreated or treated with PHCCC in soluble or NP 




Figure 7. PHCCC NPs reduce DC activation and antigen presentation. CD11c
+
 
splenocytes were stimulated with LPS (1µg/mL) and treated with soluble PHCCC 
(40M), PHCCC NPs at decreasing doses, or equivalent masses of empty NPs. After 18 
hours cells were collected and the percent of live/CD11c
+
 cells expressing (A) CD40, (B) 
CD80, (C) and CD86 were quantified by flow cytometry. (D) CD11c
+
 splenocytes were 
stimulated and treated with PHCCC NPs as in (A-C). After 18 hours, SIINFEKL peptide 
(5µg/mL) was added. Two 2 hours later, flow cytometry was used to analyze cells for the 
percent of live/CD11c
+
 cells presenting SIINFEKL in H-2kb. Samples were prepared in 
triplicate and data are representative of results from at least 3 similar experiments.  
 
expression, as well as loading and presentation of a common antigenic peptide by the 
MHC-I pathway. As shown in Figure 7A-C (green bars), PHCCC NPs significantly 
decreased CD40, CD80 and CD86 expression on DCs relative to DCs cultured only 
with LPS. These effects were dose dependent and were comparable to the reduction 
caused by soluble PHCCC. Compared with LPS-treated positive controls, empty NPs 
did not significantly alter DC activation at any concentration (Figure 7A-C, gray 






To assess the impact of PHCCC NPs on antigen presentation, DCs were 
incubated with LPS, soluble PHCCC or PHCCC NPs, and SIINFEKL peptide - a 
common model antigen derived from ovalbumin. After 20 hours, cells were stained 
with an antibody that binds SIINFEKL only when presented in MHC-I (H-2kb). 
While 81.3 ± 0.7% of cells treated with LPS and SIINFEKL presented this antigen 
via MHC-I (Figure 7D), treatment with PHCCC NPs reduced SIINFEKL 
presentation to 30.3% ± 3.0%, depending on NP dose (Figure 7D, green bars). The 
magnitude of this reduction was significant compared with cells lacking PHCCC 
treatments, but less pronounced than the reduction in SIINFEKL presentation 
observed in cells treated with soluble PHCCC (11.3 ± 4.3%). 
4.4 Polarization of T cells by PHCCC NPs in vitro 
As discussed in Section 1.3, CD4
+
 T cells are the main effector cells 
responsible for the pathology of MS, and the proliferation and differentiation of CD4
+
 
T cells is largely controlled by signals presented by DCs during an interaction with 
antigen specific T cells.  Therefore we investigated whether decreased inflammatory 
cytokine secretion, activation marker expression and antigen presentation by DCs 
treated with PHCCC NPs would polarize regulatory T cell responses. 
To determine if the effects of PHCCC NPs on DC activation and cytokine 
profiles alter T cell differentiation, we employed a co-culture model in which DCs 
from wild-type mice were cultured with splenic CD4
+
 T cells isolated from transgenic 
2D2 mice – a strain in which CD4
+
 T cell receptors are specific for a myelin 




with soluble PHCCC, PHCCC NPs, or empty NPs at equivalent polymer masses. 
After 24 hours, CD4
+
 2D2 splenocytes were added to the culture. 72 hours later, cells 
were collected and T cell proliferation was examined. DCs treated with PHCCC NPs 
drove proliferation in only 10.8 ± 0.4% of T cells (Figure 8A, green bars), a striking 
decrease compared to 55.7 ± 1.9% and 68.4 ± 0.5% observed in DCs treated with 
soluble PHCCC or those receiving only the stimulants (i.e., MOG+LPS), respectively 
(Figure 8A). Attenuation of T cell proliferation was dose dependent, but was 
significant using even at the lowest doses of PHCCC delivered in NP form (25.4 ± 
2.2%). Equivalent masses of empty particles did not cause any significant reduction 
in proliferation compared with cells treated with LPS and MOG. Mean fluorescent 
intensity (MFI) analysis of these data also confirmed PHCCC NPs significantly 
reduce proliferation (Figure 8B). 
Treatment of DCs with PHCCC NPs as in Section 4.4.2 also polarized T cell 
phenotype, shifting CD4
+











) (Figure 8C, 6D, green). At 
the highest dose, TREG levels in wells treated with PHCCC NPs were 5.7 ± 0.5%, 
compared to 3.3 ± 0.7% in samples treated with MOG and LPS, 4.5 ± 0.6% in 
samples treated with soluble PHCCC, and 3.6 ± 0.7% in cells treated with equivalent 
masses of empty particles (Figure 8C, 6D). PHCCC NPs also reduced TH17 levels. In 
cells treated with MOG and LPS, 82.1 ± 5.3% of CD4
+





), while soluble PHCCC treatment reduced ROR 
frequencies to 67.0 ± 9.9% (Figure 8E). PHCCC NPs mediated a dose dependent 








Figure 8. PHCCC NPs restrain T cell proliferation and inflammatory cytokines, 
promote TREGS, and reduce TH17 cells. CD11c
+
 cells isolated from spleens were 
stimulated with LPS (1µg/mL) in the presence of MOG peptide (10µg/mL), and treated 
with soluble PHCCC (40µM), PHCCC NPs at decreasing doses, or equivalent masses 
of empty NPs. After 18 hours, CD4
+
 splenocytes from 2D2 mice were added to culture. 
(A) CSFE dilutions of live/CD4
+
 T cells from representative co-culture samples and 
(B) mean fluorescent CSFE intensities (MFI). (C) Gating scheme and histograms of 




 cells (i.e., TREG). (D) Frequencies of TREGS 
measured for each treatment type. (E) Percentages of CD4
+
 cells expressing ROR as 
an indicator of TH17 cells. (F) IFN in supernatants. For all studies, samples were 
prepared in triplicate and are representative of at least 3 similar experiments.  
8E, green). The supernatants from these studies also revealed significant changes in 
IFN production, with PHCCC NPs reducing secretion of IFN to 390 ± 77pg/mL 
compared to 13600 ± 550pg/mL after treatment with MOG and LPS and 
8970±1110pg/mL after treatment with soluble PHCCC (Figure 8F). Together, these 
co-culture results indicate that PHCCC NPs reduce antigen specific T cell 
proliferation and cytokine response, while promoting TREGS and reducing 





4.5 PHCCC NP mediated Inhibition of autoimmune reactions in vivo 
We next evaluated whether controlled release of PHCCC from NPs could 
provide a therapeutic benefit during autoimmunity in mice, but with less frequent or 
less toxic dosing than required for soluble drug. We tested the effects of PHCCC NPs 
in the EAE model, which is the gold standard animal model for human MS. EAE is 
induced by immunizing mice with a high concentration of myelin peptide and a 
strong inflammatory adjuvant, CFA, resulting in the generation of autoreactive T cells 
which are reactive against myelin. The blood brain barrier is then opened by injection 
with pertussis toxin, allowing autoreactive T cells to enter the periphery and attack 
myelin, causing symptoms of neurodegeneration such as paralysis. A clinical score is 
assigned to each mouse daily, which is proportional to the severity of symptoms of 
neuroinflammation. The effectiveness of a therapy for reducing autoimmune reactions 
can be tested using this model by evaluating the ability of the treatment to inhibit 
neuroinflammatory symptoms as measured by a reduction in clinical score. 
In these studies, mice were induced with EAE, then injected subcutaneously 
with soluble PHCCC or PHCCC NPs every 5 days starting on the day of EAE 
induction (day 0) (Figure 9A). In this study, mice treated with soluble PHCCC or 
PHCCC NPs exhibited identical disease progression and severity (Figure 9B-E). We 
next tested a regimen in which mice received soluble PHCCC or PHCCC NPs every 
three days (Figure 9F). During this regimen, PHCCC NPs caused a statistically 
significant delay in disease onset (Figure 9G–I) and decreased disease severity 




Figure 9. PHCCC NPs delay the onset of EAE and reduce disease severity. Mice were 
induced with EAE and treated with 3mg/kg soluble PHCCC or PHCCC NPs at (A) five 
day or (F) three day intervals. Disease pathology was assessed daily using the clinical 
scale described in the methods. (B) Mean clinical score time course for mice treated using 
the regimen in (A). (C) Individual clinical scores of mice shown in (B) on day 10 and 15. 
(D) Incidence of disease (EAE score >0) for the mice in (B). (E) Maximum mean score 
observed during studies using the regimen in (A). (G) Mean clinical score time course for 
mice treated using the regimen in (F). (H) Individual clinical scores of mice shown in (G) 
on day 10 and 15. (I) Incidence of disease (EAE score >0) for the mice in (G). (J) 
Maximum mean score observed during studies using the regimen in (F). Studies were 
conducted with groups of 6 mice.  
 
not shown). In groups treated with soluble PHCCC, 100% of mice developed 
symptoms by day 13, compared to 50% for groups treated with PHCCC NPs (Figure 
9I). Additionally, the maximum mean clinical score over the extent of the study was 
lower in the PHCCC NP treated group, reaching a value of 2.5 compared to a score of 




Chapter 5:  Discussion
ǂ
 
5.1 Relevance of results for ongoing work in the field 
Several recent immunotherapies have explored controlled release to provide 
better or more targeted control over the function and phenotype of DCs or T cells. 
Some of the important drugs that have been tested in this area include MPA (75), 
rapamycin (34, 76), and 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl 
ester (ITE) (57). The current study is the first investigation of controlled release of 
small molecule metabolic enhancers to modulate immune cell function and restrain 
autoimmunity. Since glutamate is expressed at high, toxic levels during 
autoinflammation (e.g., during MS), increasing the activity of receptors such as 
mGluR4 that provide a less toxic metabolic pathway to reduce these levels can help 
address excitotoxicity and neurodegeneration (61). Of even greater relevance to our 
studies, modulating mGluR4 signaling on DCs can decrease the expression of 
activation markers and alter cytokine secretion profiles to suppress TH17-mediated 
inflammation, while driving T cells toward protective TREG phenotypes (10, 11). 
Thus, PHCCC has the potential to help address both excitotoxicity (by reducing 
glutamate levels) and inflammation (by redirecting T cell response). Toward this 
goal, we investigated the ability of controlled release of PHCCC to improve T cell 





5.2 PHCCC NPs reduce toxicity while maintaining immunomodulatory function 
During in vitro studies, PHCCC NPs exhibited several favorable properties 
compared with soluble drug. First, PHCCC could be solubilized and slowly released 
from NPs without need of solvents or other vehicles (e.g., sesame oil). PHCCC 
delivered in particle form was 36-fold less toxic, with equivalent doses in soluble 
exhibiting high levels of toxicity compared to PHCCC NPs (Figure 1F). 
Interestingly, PHCCC toxicity was almost completely eliminated when delivered in 
NP format, approaching the levels measured in unstimulated controls. This 
observation was true even at the higher concentrations required for PHCCC NPs to 
match the effectiveness of soluble PHCCC (Figure 1F). Although toxicity was absent 
when cells were treated with PHCCC NPs, clear effects on DCs (e.g., surface 
markers, cytokine profiles) and T cells were observed, indicating a modulatory 
function rather than toxicity or cell death. 
 
5.3 Effects of release kinetics on effective dose of PHCCC NPs in vitro 
 The immunomodulatory effects of soluble PHCCC on DCs were maintained 
when PHCCC was delivered in NPs, though higher concentrations had to be delivered 
to achieve the same level of change in cytokine profiles and activation marker 
expression. This observation may result from the controlled release of PHCCC from 
NPs. Soluble PHCCC delivery results in immediate availability of all drug, while 




18 hours, and while release studies show that 75% of drug was released over this 
interval under sink conditions, without the DMSO vehicle used in soluble PHCCC 
treatments (and media controls), drug release from particles likely achieved a much 
lower effective solution concentration of free drug in cell culture wells compared to 
the solution concentration in wells treated with soluble formulations containing 
DMSO. This idea may also explain why lower concentrations of PHCCC NPs were 
more effective than soluble drug in promoting TREGS, reducing IFN, and limiting T 
cell proliferation during co-culture studies that continued for 96 hours. For example, 
400µM PHCCC NP had a similar effect to 40µM soluble PHCCC on reducing DC 
activation (Figure 4A-4C), while 50µM PHCCC NP caused a larger reduction in T 
cell proliferation compared to 40µM soluble PHCCC (Figure 5A,5B). Soluble drug 
may be exhausted or degraded over this interval, whereas drug in particles may be 
more stable. The greater time for metabolism of drug in solution could also allow 
continued dissolution of PHCCC that is release from particles or that has precipitated.  
 
5.4 Potential benefits from uptake of PHCCC NPs by DCs 
 Since fluorescent analogs of PHCCC have not been reported, we studied 
uptake using NPs loaded with a fluorescent lipophilic dye as a model cargo. Our 
results demonstrate that these NPs are readily internalized by DCs (Figure 1D,1E). 
Thus, in addition to reduced toxicity, NP-mediated delivery may provide a simple 
method of targeting PHCCC to DCs residing in lymph nodes or spleen since antigen 
presenting cells are specialized to internalize particulate materials over soluble 




T cells in lymphoid organs (6, 7, 8). Thus, to polarize T cell function and ameliorate 
autoimmune responses, it may be beneficial for immunomodulatory drugs acting on 
DCs to reach the lymphoid organs and persist at sufficient concentrations in these 
tissues during (self) antigen presentation. Further, soluble delivery results in systemic 
exposure of drug, while NPs reach lymph nodes through passive drainage and 
through trafficking by DCs after NP uptake. Using PHCCC NPs that release PHCCC 
over an extended time could help target LNs and avoid systemic exposure while 
avoiding continual dosing of soluble drug. 
 
5.5 Observed effects of PLGA NP carriers on DCs and T cells 
 Although PLGA has traditionally been seen as immunologically inert, recent 
studies have demonstrated that PLGA can activate DCs and inflammasome pathways, 
amplify immune responses to toll-like receptor agonists, and cause secretion of 
inflammatory cytokines (77, 78). Thus, empty NP controls were included in all 
experiments in order to isolate any intrinsic polymer effects from the encapsulated 
PHCCC. The highest masses of empty NPs – correlating to the lowest drug to 
polymer ratios – generally had a slight suppressive effect on cytokine secretion 
(Figure 3), but minimal effects on DC activation (Figure 4) and T cell studies 
(Figure 5). Interestingly, other reports demonstrate a decrease in the expression of 
DC activation markers when DCs are treated with PLGA particles for 48 hours before 
stimulation with LPS (79). From a physicochemical standpoint, the slight effects of 
empty particles observed in our experiments at high concentrations may be driven by 




5.6 Expected and observed effects of PHCCC NP modulation of DC cytokine profiles 
and polarization of T cell phenotype 
During adaptive immune response, IL-6 and IL-12 drive proinflammatory 
function, secreted by DCs to promote TH17 and TH1 cells, respectively (81). IL-10 is 
a polyfunctional cytokine, but often serves as a negative regulator to restrain DC 
function. Although IL-10 production is a goal of many tolerogenic therapies, PHCCC 
has been shown to decrease IL-10 production in response to LPS stimulation. The 
proposed mechanism for this process is drug-mediated reduction of the cAMP 
triggered by LPS, resulting in a shift away from cytokines that drive TH17 cells and 
toward cytokines that promote TREG and TH1 (10). Therefore PHCCC is a modulator, 
and not a strict immunosuppressive agent. We observed these effects through a 
decrease in IL-6 and IL-10 secretion compared to untreated DCs stimulated with LPS 
(Figure 2, 3), but did not observe any differences in IL-12 secretion (data not shown). 
Interestingly, after LPS stimulation, IL-10 secretion was delayed compared with 
inflammatory cytokines (Figure 2D-F, 3D-F), in agreement with the natural time 
course for regulation during which IL-10 supports return of immune function to basal 
homeostatic levels following inflammation or infection events (81). 
The effects of PHCCC on DCs described above have an important impact on 
T cell differentiation and function during autoimmunity. For example, during EAE 
and MS, disease is driven by subsets of CD4
+
 helper T cells, but it is unclear whether 
TH17 or TH1 cells induce more severe pathology (81). The Di Marco group has shown 
that protective effects of PHCCC treatment on EAE coincide with a shift away from 




culture studies revealed that treatment with PHCCC NPs shifted T cells away from 
TH17 and toward TREG phenotype, while decreasing IFN (Figure 5). Thus, although 
we did not observe an increase in TH1 function (e.g., increased IFN), decreased 
levels of IFN associated with delivery of PHCCC NPs could be beneficial in 
reducing the activity of autoreactive T cells during EAE or other autoimmune 
diseases (3). 
 
5.7 Effects of release kinetics on in vivo efficacy 
 In recent studies, soluble PHCCC protected mice from EAE when injected 
daily in sesame oil as a vehicle. However, symptoms rapidly returned in less than 24 
hours when treatment was stopped for even a single day (10). Our studies 
demonstrate that when PHCCC NPs are administered every three days, these particles 
delay the onset of EAE and reduce the severity of disease compared with soluble drug 
(Figure 6F-J) or untreated mice (Figure S3). In contrast, PHCCC NPs delivered 
every 5 days had no effect on clinical score compared to untreated mice or mice 
treated with soluble PHCCC (Figure 6A-E). From a pharmacokinetic perspective, 
one possibility may be that the NPs do not provide a drug concentration in the 
therapeutic window with 5 day intervals, which based on the release studies (Figure 
1C), appear to be during a time frame over which the drug release rate is negligible.  
Although treatment with PHCCC NPs successfully delayed the onset of 
neurological symptoms, autoimmunity eventually progressed to an incidence of 
100%. This was evident through similar mean clinical scores in both PHCCC NP and 




from the Di Marco group indicating that PHCCC does not reverse established disease 
even when soluble PHCCC is administered daily starting one day after the appearance 
of neurological symptoms (68). Thus, controlled release from PHCCC NPs may 
initially be sufficient to delay symptoms, but as the concentration of PHCCC wanes 
over the 3 day interval, myelin-reactive events (e.g., T cell expansion) may increase 
to cause neurodegeneration that is not reversed even when another dose of PHCCC 
NPs is administered. This hypothesis could be studied and used to further enhance 
metabolic control over DC and T cell function by exploring polymeric materials that 
provide longer term or higher levels of release, through addition of targeting 
molecules to improve delivery to DCs or lymph nodes, or by inclusion of mGluR4 
enhancers with increased potency. An additional strategy to potentially enhance 
PHCCC mediated protection from autoimmune reactions is to encapsulate and co-
deliver myelin with PHCCC in NPs. This may further promote long lived myelin-
specific TREG cells which can suppress autoreactive T cells in the periphery, while 








 In this study we utilized an established nanoprecipitation platform to test the 
new idea that controlled delivery of a glutamate receptor enhancer could alter 
immune cell function to improve autoimmune therapy. PHCCC NPs exhibited greatly 
reduced toxicity, while maintaining the immunomodulatory effects of soluble 
PHCCC on DCs and T cells in vitro. Treatment of mice with PHCCC NPs delayed 
disease and decreased severity compared to mice treated with soluble PHCCC. More 
broadly, this report demonstrates that controlled delivery of metabolic modulators 
that alter immune cell signaling could contribute to new therapeutic options for 
autoimmunity or inflammatory disease.  
 
6.2 Future Work 
6.2.1 Investigating the mechanism of efficacy through metabolic signaling 
 The work described in Section 4.3 and Section 4.4 demonstrated that PHCCC 
NPs restrained autoimmune reactions by modulating DCs, which in turn polarized a 
regulatory T cell response. PHCCC NPs inhibited inflammatory cytokine secretion 
and expression of activation markers mediated by stimulation with the inflammatory 
signal, LPS, which is a TLR4 agonist. This investigation did not investigate the 
signaling pathways involved in the effects of the PHCCC NPs. PHCCC is a positive 




mGluR4 (62). The proposed mechanism of action is through the mGluR4 signaling-
mediated inhibition of cAMP formulation; cAMP is a secondary messenger involved 
in TLR signaling that is normally upregulated in response to LPS (62). However this 
study did not directly confirm modulation of the mGluR4 pathway on DCs.  
Toward this goal, preliminary studies were done utilizing 8-bromo-cAMP, 
which is a membrane permeable cAMP analogue.  These in vitro studies aimed to 
determine if addition of 8-bromo-cAMP to LPS-stimulated DCs would inhibit the 
effects of PHCCC treatment. This would be expected since 8-bromo-cAMP can enter 
the cell and act in place of cAMP as a secondary messenger, bypassing the effects of 
inhibited cAMP formulation from PHCCC treatment. This mechanism was probed 
with an initial assay quantifying the ability of PHCCC to inhibit IL-6 secretion of 
LPS stimulated DCs with or without the presence of 8-bromo-cAMP, using ELISA. 
DCs stimulated with LPS secreted 1516.2 ± 132.2 pg/mL of IL-6, while soluble 
PHCCC treatment reduced IL-6 secretion to 1009.5 ± 113.5 pg/mL. Addition of 8-
bromo-cAMP inhibited the effects of PHCCC treatment, as samples stimulated with 
LPS and treated with PHCCC and 8-bromo cAMP secreted levels of IL-6 similar to 




Figure 10. PHCCC signaling in the presence of 8-bromo-cAMP. CD11c
+
 cells were 
isolated from spleens, stimulated with LPS (1µg/mL) and treated with soluble 
PHCCC with or without the addition of 8-br-cAMP (100uM).  Supernatants were 
collected and the concentrations of IL-6 were measured by ELISA at 48 hours 
 
This study was repeated with the inclusion of samples treated with PHCCC 
NPs or equivalent masses of empty NPs with or without the addition of 8-bromo-
cAMP. After 48 hrs of cultures, LPS stimulated DCs secreted 2197.1 ± 108.8 pg/mL 
of IL-6, and PHCCC NP treatment reduced IL-6 levels to 1667.7 ± 94.5 pg/mL 
(Figure 11A). Addition of 8-bromo-cAMP inhibited the effects of PHCCC NPs, as 
samples treated with PHCCC NPs in the presences of 8-bromo-cAMP secreted a 
similar level of IL-6 compared to the LPS control (Figure 11A). 
 Additional studies may also use ELISA to investigate total levels of cAMP 
formulated by DCs after stimulation with LPS with or without PHCCC NP treatment, 
to confirm that PHCCC NP activity is a result of the inhibition of cAMP formulation. 
Finally, studies investigating whether PHCCC NPs affect the expression of mGluR4 




Figure 11. PHCCC NP signaling in the presence of 8-bromo-cAMP. CD11c
+
 cells 
were isolated from spleens, stimulated with LPS (1µg/mL), treated with soluble 
PHCCC, PHCCC NP(200µM), or equivalent masses of empty NPs with or without 
the addition of 8-br-cAMP (100uM).  Supernatants were collected and the 
concentrations of IL-6 were measured by ELISA at 48 hours 
 
6.2.2 Enhancing the degree of tolerance using other biomaterial carriers 
 Although treatment with PHCCC NPs inhibited the onset of symptoms of 
neuroinflammation in mice induced with EAE, the protective effects were only 
achieved when PHCCC NPs were administered every 3 days. A potential strategy to 
try to enhance the protective effects of PHCCC with even further reduction in 
treatment frequency may be to utilize alternate biomaterial delivery vehicles to tune 
the release kinetics of the drug. One hypothesis is that controlled delivery of PHCCC 
with a more gradual and extended rate of drug release may allow for enhanced 
efficacy with reduced treatment intervals. Polymers with higher hydrophobicities, 
such as polycaprolactone or PLGA with higher lactide ratios, generally allow for 
slower release kinetics of encapsulated cargos, and may be investigated to this end. 
Alternatively, liposomes have been widely used in the delivery of therapeutics and 




applications (82). Liposomes can encapsulate hydrophobic small molecules, can be 
PEGylated for enhanced circulation time and retention in the lymph nodes, and have 
the advantage of being easily formulated at a variety of sizes from the order of 20nm 
to the µm range. Additionally, liposomes can easily be functionalized with a variety 
of targeting ligands (83). 
Preliminary studies have been conducted investigating PEGylated liposomes 
as a potential carrier for the controlled delivery of PHCCC. Liposomes consisted of 
varying molar ratios of cholesterol, 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-
phosphocholine (DOPC) and poly-ethylene glycol conjugated 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000 (DSPE-PEG). 
Liposomes were formulated by dissolving and drying lipids and PHCCC in 
chloroform. Lipid films with PHCCC were then hydrated in PBS, and were subjected 
to sonication and multiple extrusions through a 200µm membrane. Liposomes 
encapsulating PHCCC were successfully synthesized using 5, 10 and 15 molar 
percentages of PEG, and a trend showing increased PHCCC loading with increasing 
molar ratios of DSPE-PEG was observed. PHCCC Liposomes formulated with 15 % 
DSPE-PEG successful encapsulated 55.3±11 µg PHCCC/mg of liposome (Table 2). 
Table 2. Properties of PHCCC liposomes synthesized with different PEG percentages  




Treatment of DCs with PHCCC liposomes after stimulation with LPS for 48 
hrs resulted in reduced IL-6 secretion as measured by ELISA. DCs stimulated with 
LPS and treated with 400µm PHCCC liposomes secreted 239.4 ± 7.0 pg/mL IL-6, 
compared to 736.9 ± 19.0 pg/mL for untreated LPS stimulated DCs and 1193.2 ± 33.0 
pg/mL for LPS stimulated DCs treated with an equivalent mass of empty liposomes 
(Figure 12A). Future work on this project will investigate effects of PHCCC 
liposomes on DC activation as well as the ability of PHCCC liposome treated DCs on 















Figure 12. PHCCC Liposomes inhibit inflammatory cytokine secretion by DCs. 
CD11c
+
 cells were isolated from spleens, stimulated with LPS (1µg/mL), treated 
with soluble PHCCC, PHCCC Liposomes(400µM), or equivalent masses of empty 
Liposomes).  Supernatants were collected and the concentrations of IL-6 were 








ǂ Portions of this chapter have been published as: Gammon JM, Tostanoski LH, 
Adapa AR, Chiu YC, Jewell CM. Controlled delivery of a metabolic 
modulator promotes regulatory T cells and restrains autoimmunity. J Control 
Release. 2015;210:169-78. 
1. Parkin J, Cohen B. An overview of the immune system. Lancet. 
2001;357(9270):1777-89. 
2. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune 
tolerance. Cell. 2008;133(5):775-87. 
3. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: Learning self-control 
in the thymus. Nat Rev Immunol. 2005;5(10):772-82. 
4. Mueller DL. Mechanisms maintaining peripheral tolerance. Nature immunology. 
2010;11(1):21-7. 
5. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 
2002;20:197-216. 
6. Paul WE. Bridging Innate and Adaptive Immunity. Cell. 2011;147(6):1212-5. 
7. Pulendran B, Ahmed R. Translating innate immunity into immunological 
memory: Implications for vaccine development. Cell. 2006;124(4):849-63. 
8. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nature 
immunology. 2011;12(6):509-17. 
9. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune 
system. Nature immunology. 2015;16(4):343-53. 
10. Allan S. DENDRITIC CELLS Tailoring T-helper-cell responses. Nat Rev 
Immunol. 2009;9(2). 
11. Steinman RM. The Dendritic Cell System and Its Role in Immunogenicity. Annu 
Rev Immunol. 1991;9:271-96. 
12. Steinman RM, Hemmi H. Dendritic cells: Translating innate to adaptive 
immunity. Curr Top Microbiol. 2006;311:17-58. 
13. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes 
through lymphatic vessels. Nat Rev Immunol. 2005;5(8):617-28. 
14. Zhu JF, Yamane H, Paul WE. Differentiation of Effector CD4 T Cell 
Populations. Annual Review of Immunology, Vol 28. 2010;28:445-89. 
15. Davidson A, Diamond B. Autoimmune diseases. The New England journal of 
medicine. 2001;345(5):340-50. 
16. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin 
Immunol. 2012;142(1):2-8. 
17. O'Shea JJ, Paul WE. Mechanisms Underlying Lineage Commitment and 
Plasticity of Helper CD4(+) T Cells. Science. 2010;327(5969):1098-102. 
18. Kimura A, Kishimoto T. IL-6: Regulator of Treg/Th17 balance. European 
journal of immunology. 2010;40(7):1830-5. 
19. Wilbanks J. Disease-modifying therapies for multiple sclerosis: Focus on future 
direction. Formulary. 2012;47(11):392-9. 




21. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of 
autoimmunity. Nature immunology. 2007;8(9):913-9. 
22. Steinman L. Multiple sclerosis: a coordinated immunological attack against 
myelin in the central nervous system. Cell. 1996;85(3):299-302. 
23. Weiner HL. Immunosuppressive treatment in multiple sclerosis. Journal of the 
neurological sciences. 2004;223(1):1-11. 
24. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: 
Natalizumab. Nat Rev Drug Discov. 2005;4(6):510-U3. 
25. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the 
prevention and treatment of autoimmune disease. Nat Rev Immunol. 
2007;7(9):665-77. 
26. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for 
immunomodulation. Nature. 2009;462(7272):449-60. 
27. Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues 
from natural immunity. Nature materials. 2013;12(11):978-90. 
28. Hunter Z, McCarthy DP, Yap WT, Harp CT, Getts DR, Shea LD, et al. A 
biodegradable nanoparticle platform for the induction of antigen-specific 
immune tolerance for treatment of autoimmune disease. ACS nano. 
2014;8(3):2148-60. 
29. Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, et al. 
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce 
potent anti-tumor responses. Biomaterials. 2015;40:88-97. 
30. Shirali AC, Look M, Du W, Kassis E, Stout-Delgado HW, Fahmy TM, et al. 
Nanoparticle Delivery of Mycophenolic Acid Upregulates PD-L1 on Dendritic 
Cells to Prolong Murine Allograft Survival. Am J Transplant. 2011;11(12):2582-
92. 
31. Moon JJ, Suh H, Bershteyn A, Stephan MT, Liu HP, Huang B, et al. 
Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent 
humoral and cellular immune responses. Nature materials. 2011;10(3):243-51. 
32. Rudra JS, Mishra S, Chong AS, Mitchell RA, Nardin EH, Nussenzweig V, et al. 
Self-assembled peptide nanofibers raising durable antibody responses against a 
malaria epitope. Biomaterials. 2012;33(27):6476-84. 
33. Lewis JS, Dolgova NV, Zhang Y, Xia CQ, Wasserfall CH, Atkinson MA, et al. 
A combination dual-sized microparticle system modulates dendritic cells and 
prevents type 1 diabetes in prediabetic NOD mice. Clin Immunol. 
2015;160(1):90-102. 
34. Maldonado RA, LaMothe RA, Ferrari JD, Zhang AH, Rossi RJ, Kolte PN, et al. 
Polymeric synthetic nanoparticles for the induction of antigen-specific 
immunological tolerance. P Natl Acad Sci USA. 2015;112(2):E156-E65. 
35. de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies AJ, et al. 
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and 
memory recall at low dose. P Natl Acad Sci USA. 2013;110(49):19902-7. 
36. Kim J, Li WA, Choi Y, Lewin SA, Verbeke CS, Dranoff G, et al. Injectable, 
spontaneously assembling, inorganic scaffolds modulate immune cells in vivo 




37. Stephan MT, Stephan SB, Bak P, Chen JZ, Irvine DJ. Synapse-directed delivery 
of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials. 
2012;33(23):5776-87. 
38. Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Lowik CWGM, Ossendorp F. 
Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic 
cells for efficient CD8(+) T cell response: A comparative study. J Control 
Release. 2014;192:209-18. 
39. Keselowsky BG, Xia CQ, Clare-Salzler M. Multifunctional dendritic cell-
targeting polymeric microparticles Engineering new vaccines for type 1 diabetes. 
Hum Vaccines. 2011;7(1):37-44. 
40. McCarthy DP, Hunter ZN, Chackerian B, Shea LD, Miller SD. Targeted 
immunomodulation using antigen- conjugated nanoparticles. Wires Nanomed 
Nanobi. 2014;6(3):298-315. 
41. Dobrovolskaia MA, Mcneil SE. Immunological properties of engineered 
nanomaterials. Nat Nanotechnol. 2007;2(8):469-78. 
42. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 
2004;4(7):499-511. 
43. Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of 
peptide subunit vaccines with a focus on Toll-like receptor agonists. Expert Rev 
Vaccines. 2010;9(2):157-73. 
44. Maldonado RA, von Andrian UH. How Tolerogenic Dendritic Cells Induce 
Regulatory T Cells. Adv Immunol. 2010;108:111-65. 
45. Andorko JI, Hess KL, Jewell CM. Harnessing Biomaterials to Engineer the 
Lymph Node Microenvironment for Immunity or Tolerance. Aaps Journal. 
2015;17(2):323-38. 
46. Johansen P, Storni T, Rettig L, Qiu ZY, Der-Sarkissian A, Smith KA, et al. 
Antigen kinetics determines immune reactivity. P Natl Acad Sci USA. 
2008;105(13):5189-94. 
47. Kwong B, Liu HP, Irvine DJ. Induction of potent anti-tumor responses while 
eliminating systemic side effects via liposome-anchored combinatorial 
immunotherapy. Biomaterials. 2011;32(22):5134-47. 
48. Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ. Localized 
Immunotherapy via Liposome-Anchored Anti-CD137+IL-2 Prevents Lethal 
Toxicity and Elicits Local and Systemic Antitumor Immunity. Cancer Res. 
2013;73(5):1547-58. 
49. Girard JP, Moussion C, Forster R. HEVs, lymphatics and homeostatic immune 
cell trafficking in lymph nodes. Nat Rev Immunol. 2012;12(11):762-73. 
50. Thomas SN. Targeting the Tumor-Draining Lymph Node with Adjuvant 
Nanoparticles for Cancer Immunotherapy. Proceedings of the Asme Summer 
Bioengineering Conference - 2013, Pt A. 2014. 
51. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting 
of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J 
Control Release. 2006;112(1):26-34. 
52. Moon JJ, Huang B, Irvine DJ. Engineering Nano- and Microparticles to Tune 




53. Clemente-Casares X, Santamaria P. Nanomedicine in autoimmunity. Immunol 
Lett. 2014;158(1-2):167-74. 
54. Santambrogio L, Strominger JL. The ins and outs of MHC class II proteins in 
dendritic cells. Immunity. 2006;25(6):857-9. 
55. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, et al. 
Microparticles bearing encephalitogenic peptides induce T-cell tolerance and 
ameliorate experimental autoimmune encephalomyelitis (vol 30, pg 1217, 2012). 
Nat Biotechnol. 2013;31(6):565-. 
56. Canton J, Neculai D, Grinstein S. Scavenger receptors in homeostasis and 
immunity. Nat Rev Immunol. 2013;13(9):621-34. 
57. Yeste A, Nadeau M, Burns EJ, Weiner HL, Quintana FJ. Nanoparticle-mediated 
codelivery of myelin antigen and a tolerogenic small molecule suppresses 
experimental autoimmune encephalomyelitis. P Natl Acad Sci USA. 
2012;109(28):11270-5. 
58. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple 
sclerosis. Nat Med. 2000;6(1):67-70. 
59. Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative 
disorder? Annu Rev Neurosci. 2008;31:247-69. 
60. Peferoen L, Kipp M, van der Valk P, van Noort JM, Amor S. Oligodendrocyte-
microglia cross-talk in the central nervous system. Immunology. 
2014;141(3):302-13. 
61. Spampinato SF, Merlo S, Chisari M, Nicoletti F, Sortino MA. Glial metabotropic 
glutamate receptor-4 increases maturation and survival of oligodendrocytes. 
Frontiers in cellular neuroscience. 2014;8:462. 
62. Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, et al. (-)-
PHCCC, a positive allosteric modulator of mGluR4: characterization, 
mechanism of action, and neuroprotection. Neuropharmacology. 
2003;45(7):895-906. 
63. Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF. Exciting Times beyond the Brain: 
Metabotropic Glutamate Receptors in Peripheral and Non-Neural Tissues. 
Pharmacol Rev. 2011;63(1):35-58. 
64. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu 
Rev Immunol. 2003;21:685-711. 
65. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for 
transplant tolerance. Nat Rev Immunol. 2007;7(8):610-21. 
66. Lutterotti A, Martin R. Antigen-specific tolerization approaches in multiple 
sclerosis. Expert Opin Inv Drug. 2014;23(1):9-20. 
67. Pacheco R, Oliva H, Martinez-Navio JM, Climent N, Ciruela F, Gatell JM, et al. 
Glutamate released by dendritic cells as a novel modulator of T cell activation. J 
Immunol. 2006;177(10):6695-704. 
68. Fallarino F, Volpi C, Fazio F, Notartomaso S, Vacca C, Busceti C, et al. 
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains 
neuroinflammation. Nat Med. 2010;16(8):897-U94. 
69. Fazio F, Zappulla C, Notartomaso S, Busceti C, Bessede A, Scarselli P, et al. 




receptor, suppresses experimental autoimmune encephalomyelitis in mice. 
Neuropharmacology. 2014;81:237-43. 
70. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis 
- a multifaceted adversary. Nat Rev Drug Discov. 2008;7(11):909-25. 
71. Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang ZX, Luo QW, et al. 
Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive 
Allosteric Modulators of Metabotropic Glutamate Receptor 4. Mol Pharmacol. 
2008;74(5):1345-58. 
72. Mendel I, Kerlero de Rosbo N, Ben-Nun A. A myelin oligodendrocyte 
glycoprotein peptide induces typical chronic experimental autoimmune 
encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta 
expression of encephalitogenic T cells. European journal of immunology. 
1995;25(7):1951-9. 
73. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, et al. Myelin-
specific regulatory T cells accumulate in the CNS but fail to control autoimmune 
inflammation. Nat Med. 2007;13(4):423-31. 
74. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo AK. Myelin 
oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop 
spontaneous autoimmune optic neuritis. J Exp Med. 2003;197(9):1073-81. 
75. Look M, Stern E, Wang QA, DiPlacido LD, Kashgarian M, Craft J, et al. 
Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus 
erythematosus in mice. J Clin Invest. 2013;123(4):1741-9. 
76. Jhunjhunwala S, Raimondi G, Thomson AW, Little SR. Delivery of rapamycin 
to dendritic cells using degradable microparticles. J Control Release. 
2009;133(3):191-7. 
77. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, et al. Uptake of 
particulate vaccine adjuvants by dendritic cells activates the NALP3 
inflammasome. P Natl Acad Sci USA. 2009;106(3):870-5. 
78. Park J, Babensee JE. Differential functional effects of biomaterials on dendritic 
cell maturation. Acta Biomater. 2012;8(10):3606-17. 
79. Lewis JS, Roche C, Zhang Y, Brusko TM, Wasserfall CH, Atkinson M, et al. 
Combinatorial delivery of immunosuppressive factors to dendritic cells using 
dual-sized microspheres. J Mater Chem B. 2014;2(17):2562-74. 
80. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, 
Andreesen R, et al. Tumor-derived lactic acid modulates dendritic cell activation 
and antigen expression. Blood. 2006;107(5):2013-21. 
81. Samarasinghe R, Tailor P, Tamura T, Kaisho T, Akira S, Ozato K. Induction of 
an anti-inflammatory cytokine, IL-10, in dendritic cells after toll-like receptor 
signaling. J Interf Cytok Res. 2006;26(12):893-900. 
82. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical 
applications. Adv Drug Deliver Rev. 2013;65(1):36-48. 
83. Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted 
liposome design: challenges and fundamental considerations. Trends Biotechnol. 
2014;32(1):32-45. 
 
